Skip to main content

Lumateperone Tosylate

Brand names: Caplyta

Atypical Antipsychotic Oral

At a glance

Medicare prescriptions, 2024
112,658
Medicare drug cost
$186.0M
Average cost per prescription
$1,651
Clinicians who prescribed it
4,522

Where it is prescribed

Loading map…

List the prescribers in any state, county, city or ZIP code →

What it is used for

CAPLYTA is indicated for: Treatment of schizophrenia in adults. Treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate. Adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.

From the FDA-approved prescribing information (label dated June 2025). Full labels on DailyMed (opens in a new tab)

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis. Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adults in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. The safety and effectiveness of CAPLYTA have not been established in pediatric patients.

The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.

Who prescribes it

All prescribers, by place, name or specialty →

Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.

Trend, 2020–2024

Medicare prescriptions rose 1,590% from 2020 to 2024.

Medicare Part D prescriptions per year, all prescribers
  • 20209,418
  • 202133,545
  • 202271,045
  • 2023118,721
  • 2024159,155

From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.

What it looks like

Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.

Intra-Cellular Therapies, Inc

StrengthLooks likeImprint
10.5 mgpink capsule, 18 mmITI 007 10 5 MG
21 mgwhite capsule, 19 mmITI 007 21 MG
42 mgwhite capsule, 22 mmITI 007 42 MG

Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.

Industry payments about this drug

Drug makers reported $16.8M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).

  • Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) $16.8M
  • Janssen Pharmaceuticals, Inc $167

See all companies →

Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor

Recalls and shortages

Not on the FDA drug shortage list.

No FDA-reported recalls since 2020.

Industry-funded trials

Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.